Gastric cancer is highly prevalent in several countries around the world and remains an incurable disease. Treatment involves surgery, chemotherapy and radiation. Surgical resection remains the definitive treatment for early stage (T1 and T2) gastric cancer, with 5-year survival rates of 70 -95%. Localized tumours that extend beyond the submucosa are, however, associated with worse outcomes and a 5-year survival rate of 20 -30%. Recent advances mainly concern chemotherapy prior to surgical resection. The goal of pre-operative chemotherapy is to allow an early attack on systemic micrometastatic disease and, by downstaging the primary tumour, to increase the percentage of patients able to undergo curative resection. Pre-operative chemotherapy remains experimental, but several phase II and III studies have shown promising results. One approach involves systemic, pre-operative chemotherapy for resectable gastric cancer. This review focuses on the development of pre-operative chemotherapy as a component of the multimodal treatment of gastric cancer.
Introduction
Despite its declining incidence in western Europe 1 and the USA, 2 gastric carcinoma remains the second most common cause of cancer death worldwide, with over 600 000 deaths per year. 3 In 2007, more than 21 260 new cases of gastric cancer were estimated to occur in the USA, with 11 210 deaths. 4 Surgical resection remains the definitive treatment for early stage (T1 and T2) gastric cancer, with 5-year survival rates of 70 -95%. 3,5 -7 Localized tumours that extend beyond the submucosa are, however, associated with worse outcomes and a 5-year survival rate of around 20 -30%. 8 Although developments in surgery have been slowed in the West by the large percentage of patients presenting at advanced stages of disease, 9 radical gastrectomy with extended lymphadenectomy 10, 11 has been performed successfully in Japan and other east Asian countries, 12 as well as at specialized centres in the West, 6,13 -16 and is now recognized as a reasonably safe procedure when performed by experienced surgeons. 5, 17 The survival benefit of extended lymphadenectomy has, however, not yet been proven in a large-scale randomized clinical trial, 18, 19 and the prognosis of patients with locally advanced gastric cancer remains poor even after potentially curative resection. Consequently, multimodal treatment strategies involving RB He, JQ Chen Pre-operative chemotherapy for gastric cancer surgery, pre-and post-operative chemotherapy, and radiation therapy have been explored to improve the survival rate of patients with resectable advanced gastric cancer. The current review focuses on the development of pre-operative chemotherapy, including state-of-the-art therapy, given as a component of such multimodal treatments for gastric cancer.
The significance of preoperative chemotherapy
Due to consistently poor outcomes in patients treated with a strategy of surgery followed by chemotherapy, pre-operative chemotherapy has for several years attracted the attention of investigators in the West. In other neoplasms, such as breast or rectal cancer, chemotherapy has proven efficacy and has been advocated at the pre-operative phase with the aim of potentially downsizing/downstaging the primary tumour to obtain advantages during surgical resection. In gastric cancer, the major treatment endpoints do not involve any less extensive surgical resection or aims of organ conservation compared with these other neoplasms, and pre-operative treatment in resectable gastric carcinoma can increase control over haematogenous metastases and decrease locoregional recurrences which, after R0 resection, still accounts for 40 -51% of cases. 20 -25 In fact, two randomized European trials have demonstrated a significant survival advantage with pre-operative chemotherapy in patients presenting with locally advanced gastroesophageal adenocarcinoma that is deemed resectable (clinical stages II and III according to International Union Against Cancer [UICC] criteria) ( Table  1) . 26, 27 Phase III studies have demonstrated that pre-operative chemotherapy can be given with acceptable toxicity and without excessive post-operative morbidity and mortality. Some adverse effects associated RB He, JQ Chen Pre-operative chemotherapy for gastric cancer with pre-operative chemotherapy, such as chemotherapy-induced anaemia necessitating pre-operative allogenic red cell transfusion, should be carefully investigated for their prognostic impact. 28 What is known from phase III trials is that patients who respond to pre-operative chemotherapy have a markedly improved prognosis compared with non-responders. Above all, pre-operative chemotherapy can improve the curative resection rate and patients' survival. 29
Standard pre-operative chemotherapy regimens
Despite a relatively high rate of objective responses achieved with cisplatin-based chemotherapy and other drug combinations for gastric cancer, including new agents, the time to treatment progression, because of disease progression, is usually short and median survival is < 11.2 months. 30 Toxicity profiles may differ considerably, depending on the chemotherapy schedule, and should be taken into account particularly when unexpected large differences in progressionfree and overall survival occur. Relatively aggressive combination regimens, such as etoposide-adriamycin-cisplatin (EAP), 5-fluorouracil (5-FU)-folinic acid-etoposidecisplatin (FLEP) or docetaxel-cisplatin-5-FU (DCF) commonly require regular use of colony-stimulating factors due to their high medullar toxicity. 31 -33 Epirubicin-cisplatin-5-FU (ECF) by continuous intravenous infusion seem to be less toxic, 34 but the need for central venous access and portable pumps makes these schedules less comfortable for the patient. Table 2 summarizes the data from some of the most frequently used combination regimens for the treatment of gastric cancer that have been studied in phase III trials 26,35 -39 Nowadays, data derived from randomized phase III studies no longer provide convincing support for the use of a specific schedule as a standard treatment. This is because, during the early 1990s, especially in Europe, 5-FU-doxorubicinmethotrexate (FAMTX) became the gold standard when it was shown to be superior in terms of overall survival when compared with the traditional 5-FU-doxorubicinmitomycin C (FAM) regimen (42 weeks vs 29 weeks regimen). 40 However, the results of five subsequent randomized trials comparing FAMTX or FAM versus cisplatin-based combinations (EAP, FLEP, cisplatin-5-FU [PF] and etoposide-epirebicin-cisplatin [EEP]) were disappointing. 41 -45 The authors concluded that none of these schedules should be regarded as standard treatment for advanced gastric cancer and that new strategies should be found.
Long-term results for the ECF regimen, which was developed in the UK, when compared with FAMTX demonstrated that ECF yielded a significantly higher response rate (46% vs 21%; P = 0.00003), median survival period (8.7 months vs 6.1 months; P = 0.0005) and 2-year survival rates (14% vs 5%; P = 0.03). 46 The results were, however, somewhat confounded by the fact that around one-third of patients included in both arms had locally advanced disease rather than metastatic disease. More patients in the ECF arm (12/47) underwent surgery compared to the FAMTX arm (5/51), and it is not clear in the study whether there were common criteria in the expert surgical panel's decisions to perform a surgical rescue after pre-operative chemotherapy. On the other hand, ECF resulted in a more favourable toxicity profile than FAMTX. Many centres in Europe are, therefore, now considering ECF as their standard practice approach. In a later UK study that compared ECF with mitomycin C-cisplatin-5-FU (MCF), over 574 eligible patients showed an RB He, JQ Chen Pre-operative chemotherapy for gastric cancer Cisplatin-S1(Japan) 36 Cisplatin 60 mg/m 2 , IV (60 min), day 8 RB He, JQ Chen Pre-operative chemotherapy for gastric cancer equivalent response rate (42.4% for ECF vs 44.1% for MCF) and median survival times (9.4 months for ECF vs 8.7 months for MCF), although quality of life assessment suggested that the ECF regimen was more tolerable. 47 Promising results from phase II studies on new drugs for the treatment of gastric cancer have led to the setting up of phase III randomized trials in order to confirm these outcomes. For example, a phase III comparison of docetaxel-cisplatin-5-FU (DCF) versus cisplatin-5-FU (PF) reported a significant advantage for DCF in terms of response rate (37% vs 25%, respectively, P = 0.01) and overall survival (9.2 months vs 8.6 months, P = 0.02). 29 A randomized phase II comparison of DCF versus docetaxelcisplatin (DC) versus ECF, conducted by the Swiss Group for Clinical Cancer Research (SAKK), concluded that DCF was the more promising schedule and should be chosen for formal comparison with ECF in a phase III study. 48 A three-arm, randomized, phase II study comparison of leucovorin (LV) 200 mg/m 2 as a 2-h infusion, followed by 5-FU 400 mg/m 2 bolus and 5-FU 600 mg/m 2 as a 22-h continuous infusion on days 1 and 2, every 14 days (LV-5-FU2), versus LV-5-FU2 plus cisplatin 50 mg/m 2 or LV-5-FU2 plus irinotecan 180 mg/m 2 showed that the overall response rates were 13%, 27% and 40%, respectively. 46 The median progressionfree survival (6.9 months) and overall survival (11.3 months) of the LV-5-FU2irinotecan regimen were encouraging when compared with those of previous randomized studies. The accrual of a randomized phase III trial comparing irinotecan plus infusional LV-5-FU versus cisplatin plus infusional 5-FU has been completed and the outcome is expected in the near future.
It remains unclear how pre-operative therapy may be integrated into the multimodal management of localized gastric cancer. Consequently, there is currently no gold standard of therapy and further phase II and III studies are necessary.
The future of pre-operative chemotherapy NEW DRUGS AND REGIMENS
New drugs and regimens are required for the treatment of gastric cancer. The advent of these, with their higher response rates, indicates that gastric cancer is chemosensitive and, therefore, from a theoretical point of view they may demonstrate greater efficacy as adjuvant therapy.
RELIABLE GENETIC MARKERS
Reliable genetic markers, at the genomic DNA, mRNA, or protein levels, that could predict the response of gastric cancer to preoperative chemotherapy, would be of great value in the selection of appropriate patients for pre-operative chemotherapy and is currently the subject of much debate. For example, Napieralski et al. 49 evaluated the expression of several therapy-related genes to predict response and survival of advanced gastric cancer patients treated with a preoperative chemotherapeutic protocol. They collected paraffin-embedded biopsies from 61 patients who received 5-FU-and cisplatinbased chemotherapies. Expression of the 5-FU-related genes for dihydropyrimidine dehydrogenase and for thymidine phosphorylase (TP), and of the cisplatinrelated gene for growth arrest and DNA damage-inducible protein 45a (GADD45A) were analysed by quantitative real-time polymerase chain reaction. The expression levels of single genes and of various combinations were tested for an association with treatment response and overall survival. The results showed a statistically significant association with treatment response in patients with a TP expression level of ≤ 347.71 × 10 -3 and a GADD45A expression level of ≤ 82.18 × 10 -3 compared with those patients who had an expression level above the respective cut-off value for one or both genes (P = 0.002). The combination of these two variables was statistically significant with respect to histopathological (P = 0.03) and clinical response evaluation (P < 0.001). The sensitivity of the combined high GADD45A and/or high TP expression levels to predict non-response was 44%, the specificity was 100% and the positive and negative predictive values were 100% and 41%, respectively. Other combinations of gene expression did not result in an improved association with response. The combined evaluation of GADD45A and TP expression levels revealed a statistically significant association with survival. Patients with relative gene expression values above the respective cut-off values of either one or both genes showed poorer survival rates (P = 0.04).
Conclusion
A well-designed, large-scale, randomized, controlled trial is needed to determine the utility of pre-operative chemotherapy. Future trials that are based on precise diagnoses and surgical procedures are required to enable adequate interpretation of the results of treatment of resectable gastric cancer. Quality control of surgery is also very important, because surgical mortality can have a major influence on results. New drugs with a high response rate and low toxicity are needed.
